Mar 4, 2024, 4:00 PM EDT
News that the Biden administration is planning to push for Americans to get the updated COVID vaccines this fall caused several vaccine manufacturers' stock prices to rise Monday.
Novavax's protein-based Coronavirus vaccine has been recommended by the US CDC for adolescents aged 12-17 years old after receiving emergency use authorization for adults in June.
Biotech company Novavax said it expects to be able to provide an Omicron-targeting vaccine in the fourth quarter of this year. Its vaccine is under FDA review.
A panel of vaccine experts recommended Novavax's COVID-19 vaccine for emergency use authorization on Tuesday, potentially paving the way for a fourth vaccine option.
Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.
Maryland-based biotech Novavax announced a delay in plans to file for U.S. FDA authorization of its COVID-19 vaccine.
Novavax’s CEO said he believes boosters will be the company’s “biggest market” in the U.S. once it receives regulatory approval for its COVID-19 vaccine.